ASP Isotopes’ UK Subsidiary, Quantum Leap Energy Ltd., Enters Early Engagement Process with UK Nuclear Regulators

Core Insights - ASP Isotopes Inc. is advancing its initiative to produce High-Assay Low Enriched Uranium (HALEU) in the UK through its subsidiary Quantum Leap Energy Ltd (QLE Ltd) [1][2] - QLE Ltd has begun early engagement with UK regulators, marking a significant step towards becoming the first commercial producer of HALEU in the UK [2][3] - The appointment of Rich Deakin as Senior Vice President and Managing Director for UK Strategic Projects is expected to enhance QLE Ltd's capabilities in the nuclear sector [4][5] Regulatory Progress - The Department for Energy Security and Net Zero (DESNZ) has confirmed QLE Ltd's eligibility to engage with the Office for Nuclear Regulation (ONR) after successful national security due diligence [2] - QLE Ltd is preparing applications for a nuclear site license and environmental permits, aiming for full licensing within this decade, contingent on regulatory progress [3] Strategic Importance - The production of HALEU is crucial for fueling advanced modular reactors, aligning with the UK's clean energy and economic growth objectives [3][5] - QLE Ltd's initiative supports the UK's ambition for clean, secure, and competitive energy, contributing to the global HALEU supply chain [5] Leadership and Expertise - Rich Deakin brings over 35 years of experience in the nuclear sector, having held senior roles in various organizations, which will be instrumental in QLE Ltd's strategic projects [4][5] - His leadership is expected to foster partnerships and technical capabilities necessary for establishing a sovereign HALEU production capability [5] Company Overview - ASP Isotopes Inc. focuses on developing technologies for isotope production across multiple industries, employing proprietary Aerodynamic Separation Process technology [6] - The company aims to enrich isotopes for both healthcare and nuclear energy sectors, with facilities in Pretoria, South Africa [6][8]